The $2M mistake a DFM review catches before tooling

The most expensive manufacturing problems in medical devices are usually designed in. They show up months later as yield loss, a tooling change or a revalidation, long after they would have been cheap to fix.

How a small design decision becomes a $2M problem

Here is how the math typically works. A molded component carries a tolerance tighter than the molding process can reliably hold. Nobody notices during prototyping, because a skilled engineer can sort, adjust and hand-select parts. Then production starts.

First-pass yield lands at 88% instead of 98%. On a $25 unit cost at 250,000 units a year, that 10-point gap is about $625,000 a year in scrap and rework. Fixing it means modifying the mold, which in turn means change control, revalidation of the process and a regulatory assessment of the change. Add $150,000 for tooling, $300,000 to $500,000 for revalidation work, and four to six months of continued scrap while it happens. Two years in, the total is well past $2M.

Five things a DFM review should check

• Tolerances against process capability. Every critical dimension should be compared to what the chosen process can actually hold, with real capability data where it exists. A tolerance the process cannot hold becomes a permanent inspection cost.
• Assembly steps that depend on one skilled person. Manual bonding, alignment and fixturing steps that work in the lab often fail when three shifts of newly trained operators run them. Each one is a yield risk and a training cost.
• Material and supplier choices. Specialty resins, single-source components and long-lead parts look fine on a bill of materials. They become supply risk at volume.
• Inspection burden. Features that can only be verified by 100% inspection or destructive testing add labor to every unit, forever.
• Cost at volume. A design that costs $40 to build at 1,000 units should have a clear path to its target cost at 100,000. If that path depends on redesign, it is better to know now.

Why timing is everything

Before tooling and design freeze, a DFM finding is a drawing change. After validation, the same change is a regulatory event. It requires change control, often revalidation, and sometimes a new submission. The engineering fix is usually the same in both cases. What changes is the cost and the calendar.

What this means for investors

For deal teams, the question to ask is simple: was a formal DFM review done before the design was frozen, and what did it find? A company that can show the review and the closed actions has already paid down a risk that otherwise sits in the cost model.

Chris Steadham is the founder of Truestead Advisors and has spent 30+ years in medical device product development, manufacturing scale-up and general management. Planning to lock a design or cut production tooling? Start a conversation.